Loading
KMT2C (Histone-lysine N-methyltransferase 2C) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Prostate cancer, Bladder & urothelial cancer and 5 more. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Histone methyltransferase that catalyses methyl group transfer from S-adenosyl-L-methionine to the epsilon-amino group of 'Lys-4' of histone H3 (H3K4). Part of chromatin remodeling machinery predominantly forms H3K4me1 methylation marks at active chromatin sites where transcription and DNA repair take place. Likely plays a redundant role with KMT2D in enriching H3K4me1 mark on primed and active enhancer elements. Location: Nucleus (UniProt). Locus 7q36.1 (HGNC).
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Prostate cancer | 4-15% | Truncating mutation in chromatin and histone modifiers | cBioPortal mutation in prostate_msk_2024: KMT2C 156 of 2,260, 6.9%; KMT2D 152, 6.7%; KDM6A 81, 3.6%. In prad_su2c_2019: KMT2C 40 of 444, 9.0%; KMT2D 37, 8.3%; KDM6A 11, 2.5%. In prad_su2c_2015: KMT2C 23 of 150, 15.3%; KMT2D 18, 12.0%. KMT2D (then called MLL2) was mutated in 8.6% of the prostate cancers in the rapid-autopsy series, where the MLL complex was shown to interact with the androgen receptor and to be required for receptor-mediated signalling (Grasso 2012). | cBioPortal (TCGA) |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
No product in the corpus is aimed at this target yet.
No trial in the corpus names this target or one of its products.
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"KMT2C" OR ABSTRACT:"KMT2C" OR TITLE:"lysine methyltransferase 2C" OR ABSTRACT:"lysine methyltransferase 2C" OR TITLE:"Histone-lysine N-methyltransferase 2C" OR ABSTRACT:"Histone-lysine N-methyltransferase 2C" OR TITLE:"KIAA1506" OR ABSTRACT:"KIAA1506" OR TITLE:"MLL3" OR ABSTRACT:"MLL3") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about KMT2C, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/kmt2c.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/kmt2c.json. Licence CC BY-NC 4.0.